EUVIMEDEUVIMED entdecken
Multizentrische StudieEvaluationsstudieOpen Access · CC BY 4.0

Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs

Alexander L Greninger iD, Allan Larcena, Amrish Patel, Brian Webster, Christina Ulen, Dallas F Green, Dana King, Deepesh Rubin Patel, Erin McElvania iD, Glenn Harnett, Imad Jandali, Jane Gibson und 15 weitere

Journal of Clinical Microbiology · 2024

DOI: 10.1128/jcm.01219-24 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Microbiology, 2024. Verfasst von Alexander L Greninger und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: COVID-19, Nasopharynx, Point-of-Care Testing, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues its largely aseasonal spread with millions of cases per year. Highly sensitive, point-of-care testing is critical for rapid detection of coronavirus disease 2019 (COVID-19) cases and initiation of antiviral therapy to avert adverse health outcomes and reduce onward transmission of the virus. While hundreds of COVID-19 diagnostics received emergency use authorization from the FDA during the pandemic, significantly fewer have navigated the course to FDA clearance or approval. Here, we determined the clinical performance of the Cepheid Xpert Xpress CoV-2 plus for detection of SARS-CoV-2 in 3,750 anterior nasal swab (NS) specimens and nasopharyngeal swab (NPS) from 32 sites in comparison to the FDA-authorized BioFire Respiratory Panel 2.1. Three-quarters of specimens collected were tested on the Xpert Xpress CoV-2 plus in the point-of-care setting. Overall positive percent agreement (PPA) was 98.1% (95% CI: 96.7%–98.9%) and negative percent agreement (NPA) was 98.3% (97.7%–98.7%). Performance of the Xpert Xpress CoV-2 plus was slightly improved in NS compared to NPS specimens, with PPA of 99.3% versus 97.0% (Fisher’s exact test, P = 0.06) and NPA of 98.3% versus 98.2% ( P = 0.89), respectively. Assay PPA was similar between untrained and trained users (98.7% vs 97.3%, P = 0.75), while NPA was slightly improved for untrained users (99.0% vs 97.6%, P = 0.0003). This study showed that Cepheid Xpert Xpress COV-2 plus is highly sensitive and specific/has high PPA and NPA for detection of SARS-CoV-2 from both NS and NPS specimens. IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to cause millions of infections and tens of thousands of deaths per year in the United States. While the FDA authorized hundreds of SARS-CoV-2 tests during the public health emergency, significantly fewer have made the transition to being cleared or approved. There continues to be a need for FDA-authorized point-of-care SARS-CoV-2 testing that can be performed by untrained users. We conducted a large prospective study of the Cepheid Xpert Xpress CoV-2 plus test for detection of SARS-CoV-2 in both nasal and nasopharyngeal swabs by trained and untrained users. The assay demonstrated excellent clinical performance characteristics and, as a result of this study, was cleared by the FDA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NasopharynxPoint-of-Care TestingSARS-CoV-2AdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleHumansInfantMaleMiddle AgedYoung AdultCOVID-19 Nucleic Acid TestingCOVID-19 TestingNoseProspective StudiesSensitivity and SpecificitySpecimen HandlingUnited States

Stichwörter der Autor:innen

COVID-19CepheidSARS-CoV-2Xpert Xpressclinical studypoint-of-carerapid

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Slidell Internal Medicine Clinic, Slidell, Louisiana, USA.
  • Innovo Research - Piedmont Healthcare, Troutman, North Carolina, USA.
  • Innovo Research - Wilmington Health, Wilmington, North Carolina, USA.
  • Advanced Pediatrics, Vienna, Virginia, USA.

ORCID-Profile: Alexander L Greninger, Erin McElvania

Zitieren

APA

Greninger, A. L., Larcena, A., Patel, A., Webster, B., Ulen, C., Green, D. F., King, D., Patel, D. R., McElvania, E., Harnett, G., Jandali, I., Gibson, J., Killion, J., Atwi, J., Bergmann, K., Slade, L., Allen Staat, M., Faron, M., Washington, M., …, & Raman, A. (2024). Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01219-24

Vancouver

Greninger AL, Larcena A, Patel A, Webster B, Ulen C, Green DF, et al. Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs. Journal of Clinical Microbiology. 2024. doi:10.1128/jcm.01219-24

BibTeX
@article{Greninger2024,
  author = {Greninger, Alexander L and Larcena, Allan and Patel, Amrish and Webster, Brian and Ulen, Christina and Green, Dallas F and King, Dana and Patel, Deepesh Rubin and McElvania, Erin and Harnett, Glenn and Jandali, Imad and Gibson, Jane and Killion, Jennifer and Atwi, Jibran and Bergmann, Kelly and Slade, Lance and Allen Staat, Mary and Faron, Matthew and Washington, Megan and Patel, Rahul and Annamalai, Rajasekaran and Ackerman, Ronald and Stewart, William P and Amador, Yuliet Mora and Rao, Deepa and Liu, Xiaohong and Raman, Aarthi},
  title = {Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs},
  journal = {Journal of Clinical Microbiology},
  year = {2024},
  doi = {10.1128/jcm.01219-24}
}
Kostenlos starten →